PMID- 27057458
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 5
IP  - 2
DP  - 2016 Feb
TI  - Trouble at the core: BRAF(V600E) drives multiple modes of T-cell suppression in 
      melanoma.
PG  - e1078966
LID - e1078966
AB  - Several studies have demonstrated that oncogenic BRAF((V600E)) promotes T-cell 
      suppression in melanoma by upregulating the transcription of a multitude of 
      immunomodulatory chemokine and cytokine genes. BRAF((V600E)) has now been shown 
      to act even more directly to evade cytotoxic T-cell recognition, by driving rapid 
      internalization of human leukocyte antigen (HLA) class I from the tumor-cell 
      surface and its intracellular sequestration.
FAU - Bradley, Sherille D
AU  - Bradley SD
AD  - Department of Melanoma Medical Oncology and Department of Immunology, Center for 
      Cancer Immunology Research, The University of Texas MD Anderson Cancer Center , 
      Houston, TX, USA.
FAU - Melendez, Brenda
AU  - Melendez B
AD  - Department of Melanoma Medical Oncology and Department of Immunology, Center for 
      Cancer Immunology Research, The University of Texas MD Anderson Cancer Center , 
      Houston, TX, USA.
FAU - Talukder, Amjad
AU  - Talukder A
AD  - Department of Melanoma Medical Oncology and Department of Immunology, Center for 
      Cancer Immunology Research, The University of Texas MD Anderson Cancer Center , 
      Houston, TX, USA.
FAU - Lizee, Gregory
AU  - Lizee G
AD  - Department of Melanoma Medical Oncology and Department of Immunology, Center for 
      Cancer Immunology Research, The University of Texas MD Anderson Cancer Center , 
      Houston, TX, USA.
LA  - eng
PT  - Journal Article
DEP - 20150825
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC4801458
OTO - NOTNLM
OT  - BRAF V600E
OT  - Cancer
OT  - Cytotoxic T cell
OT  - HLA
OT  - MHC class I
OT  - immune suppression
OT  - immunotherapy
OT  - interleukin-1
OT  - melanoma
OT  - oncogene
OT  - oncogene targeted therapies
EDAT- 2016/04/09 06:00
MHDA- 2016/04/09 06:01
PMCR- 2016/08/25
CRDT- 2016/04/09 06:00
PHST- 2015/07/27 00:00 [received]
PHST- 2015/07/28 00:00 [revised]
PHST- 2015/07/29 00:00 [accepted]
PHST- 2016/04/09 06:00 [entrez]
PHST- 2016/04/09 06:00 [pubmed]
PHST- 2016/04/09 06:01 [medline]
PHST- 2016/08/25 00:00 [pmc-release]
AID - 1078966 [pii]
AID - 10.1080/2162402X.2015.1078966 [doi]
PST - epublish
SO  - Oncoimmunology. 2015 Aug 25;5(2):e1078966. doi: 10.1080/2162402X.2015.1078966. 
      eCollection 2016 Feb.